ClinicalTrials.gg
CompletedNCT04274738Updated Aug 27, 2024

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

A Phase 1 interventional study of Mavorixafor and Ibrutinib in Waldenstrom's Macroglobulinemia, sponsored by X4 Pharmaceuticals. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.

Sponsored by X4 Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.

Enrollment
21st of 25
16 · median 48
Started
2020
with 5 others
Phase 1
7 of 25
1 open now
Registered
21st of 25
by date

Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 21st largest by enrollment, is one of 6 that started in 2020, is one of 7 in phase 1, and was the 21st registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to select the recommended dose for a randomized registrations trial.

Read the detailed description

This is an intrapatient dose-escalation study. Three dose levels of mavorixafor will be explored: 200 milligrams (mg) once daily (QD) (dose level 1), 400 mg QD (dose level 2), and 600 mg QD (dose level 3). Ibrutinib will be administered at its labeled dose for participants with WM, 420 mg orally QD. Each treatment cycle will be 28 days.

03

Conditions studied

  • Waldenstrom's Macroglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be able to sign
  • Participants must have a clinicopathological diagnosis of WM and must meet the criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's Macroglobulinemia
  • Participant' WM must have confirmed MYD88L265P and CXCR4WHIM mutations
  • Participants must have , defined as the presence of serum IgM with a minimum IgM level of greater than or equal to (≥) 2 * the (ULN)
  • Participants may be treatment naïve or have received up to 3 prior treatment regimens for WM
  • Participants must have an performance status of 0 or 1
  • Participants must meet the following organ and bone marrow requirements:

    i) greater than (>) 1,000/microliter (μL) ii) count ≥50,000/μL (platelet transfusion-independent) iii) ≥8 grams/deciliter (gm/dL) iv) and alanine aminotransferase less than or equal to (≤) 2.5 * the ULN and serum total ≤1.5 * the ULN, unless secondary to known Gilbert's Syndrome or hepatic infiltration by WM, in which case the total bilirubin must be ≤3 * the ULN and direct bilirubin ≤1.5 × the ULN v) Serum lipase ≤1.5 * the ULN vi) Serum creatinine ≤2 * the ULN or a of ≥30 milliliters (ml)/minute based on the Cockcroft-Gault equation

  • Women of (WOCBP) must have a negative pregnancy test
  • WOCBP who are heterosexually active and male participants with female sexual partners of childbearing potential must agree to use an effective method of (for example; oral contraceptives, double-barrier methods such as a condom and a diaphragm, intrauterine device) during the study and for 4 weeks after the last dose of study medication, or to abstain from sexual intercourse for this time; a woman not of childbearing potential is one who has undergone a bilateral oophorectomy or who is , defined as the absence of menstrual periods for 12 consecutive months
  • Participants must be willing and capable of complying with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Participants with symptomatic hyperviscosity syndrome; participants who undergo plasmapheresis for hyperviscosity may be considered for enrollment once IgM level is under 4,000 mg/dl
  • Participants who have known to mavorixafor or any of its components or to ibrutinib
  • Participants who have previously received a CXCR4 inhibitor or a BTK inhibitor
  • Participants who are pregnant or breastfeeding
  • Participants with an infection requiring intravenous antibiotics or hospitalization at the scheduled time of the first administration of protocol therapy
  • Participants with (HbA1c) >6.5%
  • Participants with central nervous system (CNS) lymphoma; participants with suspected CNS lymphoma should undergo appropriate diagnostic studies (magnetic resonance imaging, lumbar puncture) before enrollment to determine if CNS lymphoma is present
  • Participants with ongoing acute clinical AEs of National Cancer Institute Common Terminology Criteria for AEs () Grade >1 resulting from prior cancer therapies or participants receive prior chemotherapy within 2 weeks of initial dosing or prior hematopoietic stem cell transplantation (auto-HSCT) within 6 weeks of initial dosing
  • Participants with a history of, or positive serologies for, (HIV), or infection (participants with HBsAb positivity due to a hepatitis B virus [HBV] vaccination are eligible)
  • Participants who have had within the past 6 months, the occurrence or persistence of one or more of the following medical conditions that could not be controlled with usual medical care (for example; required emergency care or hospitalization): hypertension, diabetes, unstable angina, seizure disorder, or myocardial infarction
  • Participants with cardiac disease, including congestive heart failure consistent with Class 3 or 4; uncontrolled hypertension, clinically significant angina, clinically significant arrythmias including a history of atrial fibrillationin the last 2 years, interval using Fridericia formula of >470 milliseconds (msec) or a history of prolonged QT syndrome
  • Participants who have had within the past 6 months the occurrence of one or more of the following events: cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade 3 or Grade 4), or chronic liver disease (meeting criteria for Class B or C)
  • Participants with prior organ transplantation (prior auto-HSCT are eligible)
  • Participants who have an uncontrolled bleeding disorder or require an anticoagulant at the time of study treatment
  • Participants with active disease requiring systemic administration
  • Participants with active second . (except: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any non-hematological malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type)
  • Participants who have received an agent within 5 half-lives of the agent; if the half-life of the agent is unknown, participants must wait 4 weeks
  • Participants who require strong or moderate inhibitors or inducers of and potent P-gp inhibitors
  • Participants who require medications which are classified as sensitive CYP2D6 substrates
  • Participant who have received in the 2 weeks preceding the first dose of protocol treatment, any of the following agents:

    i) Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor ii) Systemic corticosteroids in a dose of >10 mg equivalent of prednisone daily; topical, ophthalmic, intranasal, and inhalational corticosteroids are permitted iii) Any other immunomodulating agents, including but not limited to interferon alpha, interleukin (IL)-2, mycophenolate, antibodies to tumor necrosis factor (TNF)-α, soluble TNF receptors, Janus kinase inhibitors, or IL-23 antagonists

  • Participants with any other medical, personal, social, or psychiatric condition that, in the opinion of the Investigator, may potentially compromise the safety or compliance of the participant or precludes the participant's participation in the study
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Mavorixafor and Ibrutinib

    Each participants will initially receive mavorixafor at Dose Level 1 (200 mg QD) in combination with ibrutinib 420 mg. Cohort A will comprise the first 6 participants enrolled in the study that complete at least their first cycle at Dose Level 2 (400 mg QD). Cohort A participants will start at Dose Level 1 and be allowed to dose escalate after the first cycle to Dose Level 2, if no DLTs are observed during the first cycle of each participant. Cohort B will comprise the next 6 participants enrolled into the study that complete at least their 1st cycle at Dose Level 3 (600 mg QD). Cohort B participants will start at Dose Level 1 and be allowed to dose escalate up to Dose Levels 2 and 3. Cohort C will comprise the remainder of participants enrolled up to the total of 18. Cohort C participants will start at Dose Level 1 and be allowed to escalate to 400 and 600 mg after each dose level has been deemed safe by participants from Cohort A and B.

    Drug: Mavorixafor · Drug: Ibrutinib

Interventions

  • Mavorixafor capsules will be administered per dose and schedule specified in the arm.

    Also known as: X4P-001

  • Ibrutinib capsules will be administered per dose and schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. Number of Participants With DLTs

    Time frame: Cycle 1 (28 days)

  2. Percent Change From Baseline in Immunoglobulin M (IgM) at Cycle 1

    Time frame: Baseline, at the end of Cycle 1 (cycle length = 28 days)

  3. Percent Change From Baseline in IgM at Cycle 2

    Time frame: Baseline, at the end of Cycle 2 (cycle length = 28 days)

  4. Percent Change From Baseline in IgM at Cycle 3

    Time frame: Baseline, at the end of Cycle 3 (cycle length = 28 days)

  5. Percent Change From Baseline in Hemoglobin (Hgb) at Cycle 1

    Time frame: Baseline, at the end of Cycle 1 (cycle length = 28 days)

  6. Percent Change From Baseline in Hgb at Cycle 2

    Time frame: Baseline, at the end of Cycle 2 (cycle length = 28 days)

  7. Percent Change From Baseline in Hgb at Cycle 3

    Time frame: Baseline, at the end of Cycle 3 (cycle length = 28 days)

  8. Maximum Observed Plasma Concentration (Cmax) of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  9. Cmax of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  10. Time to Reach Cmax (Tmax) of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  11. Tmax of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  12. Half-Life (t1/2) of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  13. t1/2 of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  14. Accumulation Ratio of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  15. Accumulation Ratio of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  16. Area Under the Concentration-Time Curve (AUC) of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  17. AUC of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  18. Clearance of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  19. Clearance of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  20. Volume of Distribution (Vd) of Mavorixafor

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  21. Vd of Ibrutinib

    Time frame: Pre-dose, 0.5, 1, 2, 4, 6, and 8 to 10 hours post-dose on Day 1 and Day 21 of Cycle 1, 2, and 3 (each cycle length = 28 days)

  22. Change From Baseline in AUC of Absolute Neutrophil Count (ANC) at Cycle 1

    Time frame: Baseline, at the end of Cycle 1 (cycle length = 28 days)

  23. Change From Baseline in AUC of ANC at Cycle 2

    Time frame: Baseline, at the end of Cycle 2 (cycle length = 28 days)

  24. Change From Baseline in AUC of ANC at Cycle 3

    Time frame: Baseline, at the end of Cycle 3 (cycle length = 28 days)

  25. Maximal Change From Baseline in ANC Count at Cycle 1

    Time frame: Baseline, at the end of Cycle 1 (cycle length = 28 days)

  26. Maximal Change From Baseline in ANC Count at Cycle 2

    Time frame: Baseline, at the end of Cycle 2 (cycle length = 28 days)

  27. Maximal Change From Baseline in ANC Count at Cycle 3

    Time frame: Baseline, at the end of Cycle 3 (cycle length = 28 days)

Secondary outcomes

  1. Percent Change From Baseline in Serum IgM Levels Over the Time

    Time frame: Baseline, at each cycle throughout the study (up to approximately 2 years) (cycle length = 28 days)

  2. Change From Baseline in Hgb at Over the Time

    Time frame: Baseline, at each cycle throughout the study (up to approximately 2 years) (cycle length = 28 days)

  3. Major Response Rate

    Major response rate is defined as percentage of participants with complete response + very good partial response + partial response.

    Time frame: From Baseline up to end of study (up to approximately 2 years)

  4. Number of Participants With Adverse Events (AEs)

    Time frame: From Baseline up to end of study (up to approximately 2 years)

07

Study locations

5 sites
  • Colorado Blood Cancer Institute
    Denver, Colorado 80215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02114, United States
  • Mass General Hospital Cancer Center
    Boston, Massachusetts 02114, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Athens
    Athens, 11528, Greece
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Oct 2022, 30 months.

Of 50 phase 1 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 80. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2020
First posted
Feb 18, 2020
StartActual
Apr 30, 2020
Primary completionActual
Oct 31, 2022
CompletionActual
Oct 31, 2022
Last update
Aug 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04274738
Lead sponsor
X4 Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 18, 2020
Start date
Apr 30, 2020
Primary completion
Oct 31, 2022
Completion
Oct 31, 2022
Last update
Aug 27, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mavorixafor · Ibrutinib

Start the discussion